Drug intelligence / Profile preview

SAM0021

Development stage: Unknown
Lead developer: Samsara Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

SAM0021 is a small molecule drug developed by Samsara Therapeutics that acts as an autophagy-inducing agent. It modulates beclin-1 and inhibits alpha-synuclein, a protein whose accumulation is implicated in Parkinson's disease pathology. By boosting autophagy, the natural cellular process for clearing waste and toxic proteins, SAM0021 aims to remove alpha-synuclein build-up in neuronal cells, potentially restoring motor function impaired by Parkinson’s disease. The drug targets the underlying cause of Parkinson’s by enhancing cellular self-cleaning mechanisms rather than only treating symptoms. Samsara Therapeutics is advancing SAM0021 toward clinical trials with support from The Michael J. Fox Foundation for Parkinson’s Research.

Other names: SAM-0021SAM0021SAM 0021

Targets

BECN1 (Beclin-1)SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on SAM0021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAM0021.

Explore the full profile